Involvement of human cytochrome P450 2B6 in the ω- and 4-hydroxylation of the anesthetic agent propofol

References

• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261–270
   PubMed Web of Science ®Google Scholar
• Bray RJ. Propofol infusion syndrome in children. Paediatric Anaesthesia 1998; 8: 491–499
   PubMed Web of Science ®Google Scholar
• Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995; 50: 513–559
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94: 110–119
   PubMed Web of Science ®Google Scholar
• Favetta P, Dufresne C, Desage M, Paisse O, Perdrix JP, Boulieu R, Guitton J. Detection of new propofol metabolites in human urine using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry techniques. Rapid Communications in Mass Spectrometry 2000; 14: 1932–1936
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Human cytochrome P450 enzymes. Cytochrome P450, P.R. Oritiz de Montellano. Kluwer Academic/Plenum Press, New York 1995
   Google Scholar
• Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. British Journal of Anaesthesia 1998; 80: 788–795
   PubMed Web of Science ®Google Scholar
• Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clinical Pharmacology and Therapeutics 1999; 66: 110–117
   PubMed Web of Science ®Google Scholar
• Komatsu T, Yamazaki H, Asahi S, Gillam EMJ, Guengerich FP, Nakajima M, Yokoi T. Formation of a dihydroxy metabolite of phenytoin by human liver microsomes/cytosol: Roles of cytochrome P450 2C9, 2C19, and 3A4. Drug Metabolism and Disposition 2000; 28: 1361–1368
   PubMed Web of Science ®Google Scholar
• McKillop D, Wild MJ, Butters CJ, Simcock C. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998; 28: 845–853
   PubMed Web of Science ®Google Scholar
• Mandsager RE, Clarke CR, Shawley RV, Hague CM. Effects of chloramphenicol on infusion pharmacokinetics of propofol in greyhounds. American Journal of Veterinary Research 1995; 56: 95–99
   PubMed Web of Science ®Google Scholar
• Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T. Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metabolism and Disposition 1993; 21: 1048–1056
   PubMed Web of Science ®Google Scholar
• Navapurkar VU, Skepper JN, Jones JG, Menon DK. Propofol preserves the viability of isolated rat hepatocyte suspensions under an oxidant stress. Anesthesia and Analgesia 1998; 87: 1152–1157
   PubMedGoogle Scholar
• Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Asada A. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. British Journal Clinical Pharmacology 2001; 51: 281–285
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Knott S, Ruane RJ. Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit. Xenobiotica 1991; 21: 1243–1256
   PubMed Web of Science ®Google Scholar
• Sneyd JR, Simons PJ, Wright B. Use of proton NMR spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 1994; 24: 1021–1028
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Wang QM, He YQ, Wester MR, Johnson EF, Halpert JR. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Molecular Pharmacology 2001; 59: 475–484
   PubMedGoogle Scholar
• Tanaka E, Takano Y, Inomata S, Toyooka H, Honda K. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro. European Journal of Clinical Pharmacology 2004; 60: 565–568
   PubMedGoogle Scholar
• Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications 2004; 319: 1322–1326
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Hashimato M, Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology 1999a; 73: 65–70
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metabolism and Disposition 1999b; 27: 1260–1266
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression and Purification 2002; 24: 329–337
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. Interindividual variation of cytochrome P450 2J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 2006a; 36: 1201–1209
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metabolism and Disposition 2006b; 34: 1803–1905
   PubMedGoogle Scholar
• Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, Huebert N. Bioactivation of 4-methylphenol (p-cresol) via cytochrome P450-mediated aromatic oxidation in human liver microsomes. Drug Metabolism and Disposition 2005; 33: 1867–1876
   PubMed Web of Science ®Google Scholar
• Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicology in Vitro 2001; 15: 245–256
   PubMed Web of Science ®Google Scholar